deaths (OS)

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
avelumab plus axitinib vs. sunitinib 1 certainty unassessable-29%